Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib

Cancers(2023)10.3390/cancers15153919Source: DataRank Database

Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib is a research paper published in Cancers (2023). On theSindex it has a DataRank of 0. It has been cited 8 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.92)OA: goldTopics (27)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Mehida Rojas-Alexandre,Ruth E. Hanna ORCID,Z. Ping Lin ORCID,Elena Ratner ORCID,Cai M. Roberts ORCID

Live enrichment

PubMed:37568736 PMC:PMC10417836 OpenAlex:https://openalex.org/W4385455388

American Cancer Society Postdoctoral Fellowship

Grant: 131420-PF-17-236-01-DMC

NCATS NIH HHS

Grant: UL1 TR001863

NCI NIH HHS

Grant: P30 CA016359

National Institutes of Health

Grant: 2P30CA016359-15

COMPREHENSIVE CANCER CENTER

FWCI

0.92

Citation Percentile

0.8%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/2072-6694/15/15/3919/pdf?version=1690943231

publisherhttps://www.mdpi.com/2072-6694/15/15/3919/pdf?version=1690943231

publisherhttps://www.mdpi.com/2072-6694/15/15/3919/pdf

journalhttps://doi.org/10.3390/cancers15153919

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37568736

Fields of Study

PARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentFOXO transcription factor regulation03 medical and health sciences0302 clinical medicine

Keywords

OlaparibCancer researchEpithelial–mesenchymal transitionClonogenic assayOvarian cancerPARP inhibitorHomologous recombinationDNA repairBiologyMetastasisCancerCell culturePoly ADP ribose polymeraseGeneGeneticsDrug responseEpithelial To Mesenchymal TransitionParp InhibitorsBiochemistry and Molecular Biology610Biology and Life SciencesArticle

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being